Janssen Pharmaceutica (Johnson & Johnson Innovative Medicine) Overview
Pro stress-test →Janssen Pharmaceutica is a Belgian pharmaceutical company headquartered in Beerse, Belgium, and wholly owned by Johnson & Johnson. With over 5,000 employees in Belgium, the company focuses on research and development across neuroscience, oncology, immunology, infectious diseases, and cardiovascular areas. As a key R&D and manufacturing hub for J&J, Janssen operates a vertically integrated operation spanning early discovery through drug manufacturing and global distribution.
Strategic Profile
Pro stress-test →Janssen serves as a Center of Excellence in small molecule discovery and development with world-class capabilities in Discovery, Chemical Development, Clinical Development, and Regulatory functions. The company has delivered 20 new medicines since 2011 and has redefined treatment paradigms for many serious diseases. Its strategic advantage lies in its integrated campus model combining research, manufacturing, and clinical trial infrastructure—critical to J&J's pharma strategy.
Competitive Landscape
Pro stress-test →Janssen competes in oncology, immunology, neuroscience, and adjacent therapeutic areas through J&J's Innovative Medicine division. Primary competitors include Roche, Novartis, Merck, and other integrated pharma peers. As J&J's R&D engine rather than a standalone competitor, Janssen's competitive position reflects parent-company market strength in premium therapeutic categories.
Industry Context
Janssen Pharmaceutica (Johnson & Johnson Innovative Medicine) operates in Pharmaceutical Manufacturing & Drug Development.
Key facts
Founded: 1953 · Headquarters: Beerse, Belgium · Employees: 5000+